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ABSTRACT: Sarcoptic mange, caused by Sarcoptes scabiei var. wombati, could be a significant
threat to populations of southern hairy-nosed wombats (Lasiorhinus latifrons; SHNW) in
Australia. Treatment is currently based on the off-label use of various parasiticidal drugs, with
limited clinical efficacy trials. Our primary aim was to determine the pharmacokinetic parameters
of a macrocyclic lactone, moxidectin, to assist in the development of effective treatment protocols.
Pharmacokinetic parameters were determined in four female SHNW following a single
subcutaneous injection of 0.2 mg/kg moxidectin. Blood samples were collected for 38 days
following injection (August–September 2008), for analysis using liquid chromatography and
tandem mass spectrometry. The mean peak plasma concentration occurred at 13.6 hr, with a mean
peak plasma level of 98.6 ng/ml. The mean elimination half-life was 5.03 days, resulting in a mean
areaunder the curve of 377 ng.day/ml. The peak plasma moxidectin concentration was higher than
that seen in livestock species but the plasma elimination half-life was shorter. This study suggests
that a single injection of 0.2 mg/kg moxidectin may not be sufficient to clear a mange infection in
this species.
Key words: Lasiorhinus latifrons, macrocyclic lactone, mange, marsupial, moxidectin,
pharmacokinetics, Sarcoptes scabiei, wombat.
INTRODUCTION
The earliest report of an epizootic of
sarcoptic mange in wombats, caused by
Sarcoptes scabiei var. wombati (Acari:
Sarcoptidae), was in free-living common
wombats (Vombatus ursinus)i nN e w
South Wales, Australia (Gray, 1937).
Outbreaks have been reported more
recently in the southern hairy-nosed
wombat (Lasiorhinus latifrons; SHNW;
Ruykys et al., 2009), but not in the
critically endangered northern hairy-
nosed wombat (Lasiorhinus krefftii; Bry-
ant and Reiss, 2008). Sarcoptes scabiei
burrows in the lower stratum corneum of
the skin (Arlian, 1989) and may cause mild
localized lesions or progress to a general-
ized severe crusting hyperkeratotic der-
matosis with alopecia, excoriations, deep
fissures, and secondary pyoderma (Bryant
and Reiss, 2008).
Despite the obligate parasitic nature of
S. scabiei, transmission probably occurs
after indirect contact between wombats,
which are known to share burrows (Sker-
ratt et al., 1998). The S. scabiei life cycle
takes approximately 2 wk to complete on
the host; however, all life stages can be
found in the environment and some
survive off the host for up to 3 wk under
ideal conditions of low temperature and
high relative humidity (Arlian, 1989).
Burrows are likely to enhance mite
survival off the host by providing such
conditions (Skerratt et al., 1998).
Sarcoptic mange is the major infectious
disease of the Vombatidae (Hartley and
English, 2005). In common wombats,
epizootics can dramatically reduce local
abundance and threaten the survival of
small, isolated populations (Skerratt,
2003). The SHNW has a limited, patchy
distribution, and sarcoptic mange can
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643cause significant morbidity and mortality,
with substantial effects on local abundance
(Taggart and Temple-Smith, 2008; Ruykys
et al., 2009). There are also significant
welfare implications for severely affected
wombats. Treatment of mange can be
important in wildlife conservation pro-
grams (Wobeser, 2002); however, dosages
are often based on anecdotal experience,
extrapolations, and allometric scaling
(Mayer et al., 2006). Macrocyclic lactones,
such as ivermectin and moxidectin, can
effectively treat wombats with sarcoptic
mange (Skerratt, 2003; Skerratt et al.,
2004; Ruykys, 2005; Bryant and Reiss,
2008), but pharmacokinetic studies have
not been performed. Although the chem-
ical structure and apparent pharmacoki-
netic behavior of these compounds may
show differences, the overall pharmacoki-
netic and efficacy patterns show similari-
ties (Lanusse and Prichard, 1993). Clinical
trials using moxidectin have not been
performed; however, Ruykys (2005) found
that one subcutaneous (SC) injection of
ivermectin at 0.2 mg/kg cleared mild to
moderate mange in L. latifrons. Skerratt et
al. (2004) also found that mild mange in V.
ursinus was cured by one injection of
ivermectin at a higher dose (0.4 mg/kg),
though retreatment was required in mod-
erate mange. In another study, Skerratt
(2003) used 0.3 mg/kg of ivermectin to
treat cases of differing severity in V.
ursinus and found that three treatments
10 days apart were generally effective,
with a second course required in severe
cases. Reinfection may occur from the
environment (Arlian, 1989) or when eggs
hatch up to 7 days posttreatment, as
macrocyclic lactones are not effective
against mite eggs (Arends et al., 1999;
Papadopolous et al., 2000).
Pharmacokinetics refers to the study of
the bodily absorption, distribution, metab-
olism, and elimination of drugs (Lanusse
and Prichard, 1993). The role of pharma-
cokinetic studies in assessing the efficacy
of parasiticidal drugs relies on the as-
sumption that plasma concentration pro-
files reflect the active concentration pro-
files at the site of parasite location
(Lifschitz et al., 1999). In general, tissue
and plasma concentrations of moxidectin
exhibit a parallel time-profile disposition,
with levels in tissue (including skin and
hair) being higher and persisting for
longer than levels in plasma (Lifschitz et
al., 1999).
Data relating to the minimum inhibitory
drug concentrations required for effective
treatment of microorganisms does not
exist for parasites, presenting difficulties
when determining dosages for antiparasit-
ic drugs (Lifschitz et al., 1999). We rely on
clinical trials of efficacy, in combination
with pharmacokinetic data, to develop
drug dosage protocols. Therefore, the
primary aim of this study was to determine
the pharmacokinetic parameters and the
plasma drug disposition profile of mox-
idectin in the SHNW following SC
administration. Because SHNW have a
metabolic rate of only 42% of the predict-
ed eutherian level (Wells, 1978), we
hypothesized that the elimination half-life
of moxidectin from SHNW plasma would
be longer than livestock species.
MATERIALS AND METHODS
Animal handling and sample collection
Four female SHNW were acquired from
the Murraylands region of South Australia
(34u559S, 139u289E). They were captured at
night using a ‘‘stunning’’ technique (Taggart et
al., 2003) and acclimatized to captive condi-
tions for 3 mo, until displaying stable food
consumption and bodyweight. To enable
handling and blood sample collection, wom-
bats were anesthetized with zolazepam/tileta-
mine (3–6 mg/kg intramuscular, Zoletil 100H;
Virbac Animal Health, Milperra, New South
Wales, Australia; Taggart et al., 2005). During
the first 24 hr of the blood collection regimen
all wombats were also anesthetized using
isoflurane (3.5%) delivered in oxygen (2 l/
min) via face mask for approximately 2 min
prior to each venipuncture. Blood was col-
lected from the cephalic vein using 22-gauge
needles, placed into heparinized tubes (BD
lithium heparin VacutainerH, Franklin Lakes,
New Jersey, USA), and then centrifuged at
approximately 1200 3 G for 15 min. The
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in plain plastic tubes and analyzed within 3 wk
of collection.
On day 0 each wombat was given 0.2 mg/kg
moxidectin (CydectinH injectable, Virbac An-
imal Health, Milperra, New South Wales,
Australia) injected subcutaneously in the groin
region. Blood samples were taken before and
at 2, 4, 6, 8, 12, and 24 hr posttreatment, and
then on day 2, 4, 7, 10, 21, 30, and 38 (August
2008 to September 2008). Preliminary exper-
iments determined that beyond this time, the
levels of moxidectin in the plasma would be
below the limit of quantification of this
analytical method for measuring moxidectin.
Liquid chromatography–tandem mass
spectrometry (LC-MS-MS)
The solvents used during the analysis,
acetonitrile (ACN; J.T. Baker, Mallinckrodt
Baker Inc., Phillipsburg, New Jersey, USA)
and formic acid (98%, Fluka, Sigma-Aldrich
Corp., St. Louis, Missouri, USA), were of high
performance liquid chromatography grade.
Water was purified with a Milli-Q system
(Millipore, Billerica, Massachusetts, USA). A
10 mg/ml commercial solution of moxidectin
(CydectinH injectable, Virbac Animal Health,
New South Wales, Australia) was utilized as
the primary analyte and a 120 mg/ml com-
mercial solution of selamectin (RevolutionH,
Pfizer Animal Health, West Ryde, New South
Wales, Australia) as the internal standard. The
chromatographic system consisted of an SCL-
10AVP controller, LC-10ADVP pump, and
SIL-HTc AutoSampler (all from Shimadzu
Corporation, Columbia, Maryland, USA), con-
nected to a triple quadrupole API
TM 3000 LC-
MS-MS mass spectrometer (Applied Biosys-
tems Inc., Foster City, California, USA). The
mass spectrometer was operated in positive
electrospray ionization mode with the temper-
ature of the nebulizer set at 250 C. A mobile
p h a s ec o n s i s t i n go fA C N : H 2O:formic acid
(90:10:0.1) was pumped through an Alltech
Alltima HP C18 HL column (50 mm 3 2.1 mm,
3-mm particle size, Grace, Deerfield, Ilinois,
USA) at 0.2 ml/min at ambient temperature.
Peak area ratios (area of analyte/area of
internal standard) were used to estimate the
moxidectin concentration in spiked and exper-
imental samples.
Calibration standards were prepared fresh
in drug-free plasma at nominal concentrations
of 1, 2, 5, 10, 20, 50, 80, and 100 ng/ml; quality
controls (QCs) were prepared using a separate
working standard at 2.5, 15, and 75 ng/ml, plus
blank and internal standard only samples.
Unknown samples, standards, and quality
controls (duplicate 100 mlo fe a c h )w e r e
prepared by combining with 50 ml of internal
standard stock solution and 200 ml of ACN,
mixing on a vortex mixer and centrifuging
at approximately 2,500 3 G (Varifuge 3.0,
Heraeus-Sepatech, Osterode, Germany) for
10 min at 4 C. The supernatant was trans-
ferred to a new tube and mixed with 100 ml
H2O, and 50 ml was injected into the LC-MS-
MS system. The retention times were approx-
imately 3 min for the analyte and 4.7 min for
the internal standard and the overall run time
was 10 min.
The linear regression lines for moxidectin in
the range between 1 ng/ml and 100 ng/ml
showed an average correlation coefficient (r)
of 0.9983 over three analytical runs. The
intraday accuracy and precision using low,
medium, and high QC samples in replicates of
six were within acceptable limits (Shah et al.,
2000). The QC samples assayed in duplicate
for each analytical run were found to be within
10% of their nominal values when back-
calculated from the calibration curve. The
validated lower limit of quantification was 1 ng/
ml. One freeze–thaw cycle caused changes in
measured concentrations of less than 5%.
Pharmacokinetic and statistical analyses
Concentrations of moxidectin in the plasma
of individual animals were evaluated by
noncompartmental analysis using WinNonlin
(Version 5.2., Pharsight Corporation, Moun-
tain View, California, USA). The peak con-
centration (Cmax)a n dt h et i m et op e a k
concentration (Tmax) were read from the
plotted concentration-time curve for each
animal. The terminal rate constant (k) was
calculated from the last three data points of
the concentration-time curves. The terminal
(elimination) half-life (T1/2(el)) was calculated
as
T1=2(el)~
ln(2)
kel
The areas under the concentration-time curves
(AUC) were calculated using the trapezoidal
rule (Gibaldi and Perrier, 1982) and further
extrapolated to infinity by dividing the last
experimental concentration by the terminal
rate constant (k). The SC mean residence time
(MRT) for moxidectin was calculated as
MRTSC~
AUMC
AUC
where AUC is as defined previously, and the
area under the first moment curve (AUMC) is
defined as the AUC of the product of time and
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od of Riegelman and Collier, 1980).
RESULTS
The individual and mean profiles of
c o n c e n t r a t i o no fm o x i d e c t i ni np l a s m a
against time are shown in Fig. 1. Mox-
idectin was detected in plasma between
2 hr and 30 days postadministration.
Individual and mean pharmacokinetic
parameters are given in Table 1. The peak
plasma concentration occurred at a mean
of 13.6 hr, with a mean peak plasma level
of 98.6 ng/ml, and the mean AUC was
377 ng?day/ml. Thereafter, the plasma
concentration decreased progressively
with a mean elimination half-life of
5.03 days. Half-lives in the four SHNW
studied ranged from 2 days to 9.5 days.
DISCUSSION
Our primary aim was to determine the
concentration of moxidectin in plasma over
time, as reflected in the AUC, and the half-
life for its elimination from plasma follow-
ing a single SC dose of 0.2 mg/kg
moxidectin. To maintain concentrations
over an approximate twofold range (from
maximum to minimum values), it is gener-
ally required that dosing intervals be
similar to the half-life of a drug (Birkett,
1998). Thus, our data validate a dosing
protocol recommended by Bryant and
Reiss (2008; i.e., 0.2–0.3 mg/kg weekly,
until 2 wk after negative skin scrapings are
obtained). Based on a plasma half-life of
approximately 5 days in the SHNW, this is
the regimen most likely to maintain rea-
sonably consistent plasma levels and
achieve reliable elimination of sarcoptic
mange infections in situations where it is
possible to repeatedly treat individuals (i.e.,
captivity). When these results are assessed
in the context of the life cycle and off-host
survival of S. scabiei, it is unlikely one
injection of 0.2 mg/kg moxidectin would
reliably clear a mange infection, due to the
pressure of immediate reinfection by mites
in the environment and eggs hatching on
the animal. Clinical trials will be required
in order to verify these assumptions.
The plasma elimination half-life of
moxidectin in the SHNW was shorter
and the peak concentration was higher
than values cited for cattle, goats, and
FIGURE 1. Individual (gray symbols) and mean (black symbols) plasma concentrations of moxidectin
obtained after subcutaneous administration of 0.2 mg/kg moxidectin to four southern hairy-nosed wombats
(Lasiorhinus latifrons), August 2008 to September 2008, Adelaide, South Australia. Error bars represent
standard error.
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nusse et al., 1997; Escudero et al., 1999;
Barber et al., 2003). The hypothesis that
the elimination half-life of moxidectin
from SHNW plasma would be longer than
livestock due to the lower metabolic rate
of the wombat was therefore rejected. In
addition to metabolic clearance of mox-
idectin, other factors such as absorption
from the injection site (dependent on the
tissue characteristics and degree of perfu-
sion of the site by blood) and pattern of
distribution throughout the body may all
contribute in variable degrees to half-life.
The SHNW also demonstrate significant
digestive and renal physiologic adaptations
to their semiarid lifestyle (Hume and
Barboza, 1998; Wells and Green, 1998;
Taggart and Temple-Smith, 2008) that
may contribute to pharmacokinetic pa-
rameters assessed in this species. Lipo-
philic compounds such as moxidectin will
be preferentially sequestered into adipose
tissue and this contributes to their persis-
tence. The levels of body fat that would be
considered normal in livestock are unlikely
to be encountered in wild wombats, thus it
cannot be assumed that lipophilic com-
pounds will persist to a similar degree. In
sheep and pigs, moxidectin is less persis-
tent in thin compared to fat animals
(Craven et al., 2002a). This study supports
the notion that the ratio of fat to body
weight influences the pharmacokinetics of
lipophilic macrocyclic lactones (Craven et
al., 2002a, b; Barber et al., 2003) more
than metabolic rate. Body condition indi-
ces correlate poorly with body fat levels in
wombats (Woolnough et al., 1997), which
would make this difficult to investigate in
clinical trials.
To control mange in wild wombat
populations, it is important to know wheth-
er a single treatment is likely to eradicate S.
scabiei infection, because retreatment is
difficult. If one treatment does not elimi-
nate mites, then the welfare of the
individual may not be addressed adequate-
ly. Ineffective treatments could extend the
period of infectivity of diseased individuals
within populations and encourage devel-
opment of resistant parasites, while exces-
sive dosing may waste resources and cause
toxicity in compromised individuals. Al-
though reinfection of a successfully treated
individual in the wild could occur, it has
been shown that dogs medically cured of a
sarcoptic mange infection are less suscep-
tibletoinfection when rechallenged (Arlian
et al., 1996). Skerratt et al. (2004) proposed
the possibility of halting the transmission of
S. scabiei within a wombat population by
reducing the average intensity of infection
to a low level, via removal of moderate to
severely parasitized animals, and treatment
of the remainder with an effective long-
acting acaricide. Our results do not suggest
that a single injection of 0.2 mg/kg mox-
idectin in wild wombats could achieve such
an outcome.
Treatment of disease in fragmented
wildlife populations may become impor-
tant as continuing threats negatively im-
pact habitat and fauna. To this end,
TABLE 1. Individual and mean pharmacokinetic parameters obtained after subcutaneous administration of
0.2 mg/kg moxidectin to four southern hairy-nosed wombats (Lasiorhinus latifrons), during August 2008 to
September 2008 in Adelaide, South Australia.
Kinetic parameters
a Wombat 1 Wombat 2 Wombat 3 Wombat 4 Mean6SE
Cmax (ng/ml) 142 109 87.7 55.7 98.6618.2
Tmax (hr) 12.4 12.6 25.0 4.50 13.664.30
T1/2(el) (day) 4.40 2.06 4.14 9.52 5.0361.59
AUC total (ng?day/ml) 461 334 419 295 377638.2
MRT(SC) (day) 4.52 3.09 5.13 9.58 5.5861.40
a Cmax 5 maximum plasma concentration; Tmax 5 time to maximum plasma concentration; T1/2(el) 5 elimination half-life;
AUC total 5 area under the curve; MRT 5 mean retention time; SC 5 subcutaneous.
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in wombats may play a crucial role in their
conservation. This study is the first phar-
macokinetic trial in a wombat species and
these results add objectivity to decisions
about mange treatment in wombats. Fur-
ther studies should compare the pharma-
cokinetic parameters of oral, injectable,
topical, short-acting, and long-acting for-
mulations of macrocyclic lactones in the
wombat and utilize clinical trials to
determine the effectiveness of various
treatment protocols.
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